All In Biotech

Drug Trial Radar · NCT03373903

Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly

A Multicenter, Dose-finding Study to Determine if Oral BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in Elderly Subjects

Last checked: Nov 19, 2026Latest source record: May 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 652 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

652

Actual

Start

Nov 15, 2017

Primary completion

May 3, 2018

Study completion Jul 2018

Sponsor

Lead sponsor
Restorbio Inc.Industry
Sponsor type
Industry
First posted
Dec 14, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.

Conditions

  • Respiratory Tract Infections

Interventions

  • PlaceboOther

    oral

  • BEZ235Drug

    oral

  • BEZ235 plus everolimus (RAD001)Drug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of subjects with 1 or more laboratory-confirmed RTIs through Week 16Time frame: 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Heartland Research Associates

    Wichita, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.